Quarter

Abcourt Announces its Results for the Second Quarter ended December 31, 2023

Retrieved on: 
Tuesday, February 27, 2024
Giant, Sleeping Giant, ABI, Quarter, Investment, TMX Group, Bank statement, Letter, Insurance

ROUYN-NORANDA, Quebec, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Abcourt Mines Inc. (“Abcourt” or the “Corporation”) (TSX Venture: ABI) announces its results for the three months ended December 31, 2023.

Key Points: 
  • ROUYN-NORANDA, Quebec, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Abcourt Mines Inc. (“Abcourt” or the “Corporation”) (TSX Venture: ABI) announces its results for the three months ended December 31, 2023.
  • Highlights for the Quarter ended December 31, 2023
    Investments of $1,571,293 in exploration and evaluation during the quarter ending December 31, 2023.
  • Working capital of the Company of $(4,611,593) compared to $(4,476,223) as of June 30, 2023.
  • On November 22, 2023, the Company announces the start-up of the Sleeping Giant mill and the processing of the first tonnes from the Pershing-Manitou deposit.

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
PEGASUS, Quarter, EMA, Committee, ALS, APLS, Recurrence, AAO, ASH, Note, Physician, FDA, Marketing, Data, Treasury, Safety, CAD, Society, VALIANT, Cold agglutinin disease, CHMP, European Medicines Agency, Administration, Patient, Public expenditure, Webcast, GALE, PRINCE, PNH, ASN, Research, Travel, American Academy, Pharmaceutical industry

Cost of sales was $19.9 million for the fourth quarter of 2023, compared to $2.9 million for the fourth quarter of 2022, respectively.

Key Points: 
  • Cost of sales was $19.9 million for the fourth quarter of 2023, compared to $2.9 million for the fourth quarter of 2022, respectively.
  • R&D expenses were $69.3 million for the fourth quarter of 2023, compared to $99.4 million for the fourth quarter of 2023.
  • G&A expenses were $141.7 million for the fourth quarter of 2023, compared to $84.4 million for the fourth quarter of 2022.
  • Apellis will host a conference call and webcast to discuss its fourth quarter and year end 2023 financial results and business highlights today, February 27, 2024, at 8:30 a.m.

Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress

Retrieved on: 
Tuesday, February 27, 2024
SAN, Ulcerative colitis, Quarter, Week, CDAI, Peripheral, Blood, Obesity, ALS, Research and development, Cryopyrin-associated periodic syndrome, NLRP3, Volunteering, Inflammation, Modulation, Multiple sclerosis, Rheumatology, Safety, UC, CAPS, CNS, Administration, Pharmacokinetics, Patient, TYK2, FCAS, G&A, Ulcer, Pharmaceutical industry

SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent pipeline and business progress.

Key Points: 
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash Position: Cash, cash equivalents and marketable securities were $252.2 million as of December 31, 2023.
  • Research and Development (R&D) expenses: R&D expenses were $42.0 million for the fourth quarter of 2023, compared to $30.2 million for the fourth quarter of 2022.
  • General and Administrative (G&A) expenses: G&A expenses were $8.3 million for the fourth quarter of 2023, compared to $8.4 million for the fourth quarter of 2022.
  • Net loss: Net loss was $46.8 million for the fourth quarter of 2023, compared to $35.2 million for the fourth quarter of 2022.

Sezzle Fourth-Quarter and Fiscal Year 2023 Results

Retrieved on: 
Monday, February 26, 2024
International, Internet, Culture, Adjustment, Yoy, GAAP, UMS, Creativity, Quarter, Hand, Bookkeeping

Minneapolis, MN, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Sezzle Inc. (NASDAQ:SEZL) (Sezzle or Company) // Purpose-driven digital payment platform, Sezzle, is pleased to provide the market with an update on key financial metrics for the quarter and year ended December 31, 2023.

Key Points: 
  • Minneapolis, MN, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Sezzle Inc. (NASDAQ:SEZL) (Sezzle or Company) // Purpose-driven digital payment platform, Sezzle, is pleased to provide the market with an update on key financial metrics for the quarter and year ended December 31, 2023.
  • “Our success did not happen overnight, nor was it easy, but it occurred through creativity, dedication, and hard work from each person at Sezzle.
  • As of December 31, 2023, Sezzle had $70.7 million of cash on hand ($3.1 million restricted) and $95.0 million drawn on its $100.0 million credit facility.
  • This 4Q23 business update has been approved by the Company’s Executive Chairman and CEO, Charlie Youakim, on behalf of the Sezzle Inc. Board.

Clover Health to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

Retrieved on: 
Monday, February 26, 2024
Quarter, Webcast, Conference

FRANKLIN, Tenn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will report fourth quarter and full year 2023 financial results after market close on Tuesday, March 12, 2024.

Key Points: 
  • FRANKLIN, Tenn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will report fourth quarter and full year 2023 financial results after market close on Tuesday, March 12, 2024.
  • Management will host a conference call and webcast at 5:00 p.m. Eastern Time on March 12, 2024 to discuss the Company’s business and financial results.
  • Fourth Quarter and Full Year 2023 Conference Call and Webcast Details:
    Dial In: To access the call via telephone please dial 800-579-2543 (for U.S. callers) or 785-424-1789 (for callers outside the U.S.) and enter the conference ID: CLOVQ423

Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, February 22, 2024
EMANATE, New Drug Application, Investment, Obesity, BMI, Webcast, Initiate, BBS, Stage 2, Hyperpigmentation, Documentation, Polyphagia, European, GAAP, European Medicines Agency, PCSK1, Type, Type 2, G&A, LG Chem, BV, Completeness, Shanda, Bardet–Biedl syndrome, Clinical trial, LEPR, Medicaid, IND, Prescription, Research, Hunger, Acquisition, Quarter, EMA, MC4R, FDA, Prevalence, PMDA, Patient, POMC, Body mass index, Pharmaceutical industry

-- Acquired global rights to oral MC4R agonist LB54640 from LG Chem --

Key Points: 
  • ET --
    BOSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2023.
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash Position: As of December 31, 2023, cash, cash equivalents and short-term investments were approximately $275.8 million, as compared to $333.3 million as of December 31, 2022.
  • S,G&A Expenses: S,G&A expenses were $32.4 million in the fourth quarter of 2023 and $117.5 million for the year ended December 31, 2023, compared to $26.3 million in the fourth quarter of 2022 and $92.0 million for the year ended December 31, 2022.
  • ET today to review its fourth quarter and year end 2023 financial results and recent business activities.

Cherry Hill Mortgage Investment Corporation Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 7, 2024
Professional Services, Residential Building & Real Estate, Commercial Building & Real Estate, Finance, Construction & Property, REIT, Banking, Quarter, Investment, Partnership, Highlight, EAD, GAAP, IRS, MSR, Treasury, RMBS, TBA, Holding company

The RMBS portfolio had a book value of approximately $1.0 billion and carrying value of approximately $1.0 billion at quarter-end December 31, 2023.

Key Points: 
  • The RMBS portfolio had a book value of approximately $1.0 billion and carrying value of approximately $1.0 billion at quarter-end December 31, 2023.
  • As of December 31, 2023, Cherry Hill’s GAAP book value was $4.53 per diluted share, net of the fourth quarter dividend.
  • On December 8, 2023, the Board of Directors declared a quarterly dividend of $0.15 per share of common stock for the fourth quarter of 2023.
  • The following table provides a reconciliation of net income to EAD for the three months ended December 31, 2023 and September 30, 2023:

Grupo Supervielle Reports 4Q23 Results

Retrieved on: 
Wednesday, March 6, 2024
Banking, Professional Services, Insurance, Finance, Social support, Repurchase agreement, NPS, International trade, Coverage, Mining, Central bank, Annual report, Growth, Tier 1 capital, Sale, Disclosure, ESG, Government, ROE, Net income, Yoy, Central Bank of Myanmar, The Rev, Asset, SME, Quarter, Risk-weighted asset, Common equity, BYMA, IOL, QR, NPL, NIM, Bank

Grupo Supervielle S.A. (NYSE: SUPV; BYMA: SUPV), (“Supervielle” or the “Company”) a universal financial services group headquartered in Argentina with a nationwide presence, today reported results for the three and twelve-months period ended December 31, 2023.

Key Points: 
  • Grupo Supervielle S.A. (NYSE: SUPV; BYMA: SUPV), (“Supervielle” or the “Company”) a universal financial services group headquartered in Argentina with a nationwide presence, today reported results for the three and twelve-months period ended December 31, 2023.
  • Starting 1Q20, the Company began reporting results applying Hyperinflation Accounting, in accordance with IFRS rule IAS 29 (“IAS 29”) as established by the Central Bank.
  • Commenting on fourth quarter 2023 results, Patricio Supervielle, Grupo Supervielle’s Chairman & CEO, noted: “We closed the year with a strong quarter delivering record high ROAE of 27% in real terms, even as we navigate a complex macro and political environment characterized by high inflation, market volatility, and weak loan demand.
  • The total NPL ratio was 1.2% in 4Q23 improving 230 and 50 bps from 3.5% in 4Q22 and 1.7% in 3Q23, respectively.

Sila Realty Trust, Inc. Fourth Quarter and Year Ended 2023 Results

Retrieved on: 
Wednesday, March 6, 2024
REIT, Hospitals, Health, Commercial Building & Real Estate, Construction & Property, Investment, FFO, Quarter, GAAP, Renting, Growth, Exercise, Tenant, Core, NOI

Sila Realty Trust, Inc. today announced operating results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Sila Realty Trust, Inc. today announced operating results for the fourth quarter and year ended December 31, 2023.
  • Highlights of the Quarter Ended December 31, 2023 vs. December 31, 2022
    Rental revenue was $45.9 million, an increase of 5%.
  • Highlights of the Year Ended December 31, 2023 vs. December 31, 2022
    Rental revenue was $189.1 million, an increase of 5%.
  • The Company declared distributions per share of common stock in the amount of $0.40 for the year ended December 31, 2023.

Kingston Technology Tops Channel SSD Market Share for 2023

Retrieved on: 
Wednesday, March 6, 2024
Data Management, Semiconductor, Consumer Electronics, IOT (Internet of Things), Technology, Other Technology, Hardware, Flash, PCI Express, SSD, NVM Express, Multimedia, NV2, Growth, Digital, Kingston Technology, Solid-state drive, Quarter, SATA, Video game

This consistent performance has resulted in securing a 23.8% market share in the channel SSD market for 2023.

Key Points: 
  • This consistent performance has resulted in securing a 23.8% market share in the channel SSD market for 2023.
  • View the full release here: https://www.businesswire.com/news/home/20240306056286/en/
    Kingston Technology announces it maintained the #1 spot for channel SSD market share in 2023; thanks to its strong relationship with suppliers, customers, and partners.
  • (Photo: Business Wire)
    Data gathered by TRENDFOCUS confirmed Kingston as the number one client SSD vendor in the channel for unit market share, with 27.4 million client SSDs shipped in 2023.
  • Q4 alone saw Kingston’s client SSD market share at 21.3% and 5.7 million units shipped.